For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
03
09
2018
revised:
12
09
2018
accepted:
21
09
2018
pubmed:
29
9
2018
medline:
20
11
2019
entrez:
29
9
2018
Statut:
ppublish
Résumé
Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.
Identifiants
pubmed: 30262506
pii: 1078-0432.CCR-18-2690
doi: 10.1158/1078-0432.CCR-18-2690
doi:
Substances chimiques
TLR4 protein, human
0
Toll-Like Receptor 4
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1127-1129Commentaires et corrections
Type : CommentOn
Informations de copyright
©2018 American Association for Cancer Research.